C4 Therapeutics, Inc.
Company Stats
- Market Cap
- $409.7M
- as of Sep 30, 2026
- Shares Outstanding
- 123.0M
- Free Float
- 88.4%
Income Statement
- Revenue
- $35.9M
- Operating Income
- -$115.2M
- Net Income
- -$105.0M
- EBITDA
- -$113.7M
- Revenue Growth, 3Y
- 5.0%
- FCF Margin, 3Y Avg
- -327.6%
- FCF Margin, Worst Year
- -523.0%
Cash Flow
- Free Cash Flow
- -$99.3M
- FCF Yield
- -24.2%
- Owner FCF Yield
- -28.9%
Balance Sheet
- Cash & Equivalents
- $74.6M
Returns & Capital
- Share Repurchases
- $193,000
- Buyback Yield, 3Y Avg
- 0.0%
- SBC, 3Y Avg
- $25.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $35.9M | -$99.3M | -276.2% |
| FY2024 | $35.6M | -$65.3M | -183.6% |
| FY2023 | $20.8M | -$108.5M | -523.0% |
| FY2022 | $31.1M | -$111.4M | -358.4% |
| FY2021 | $45.8M | -$88.2M | -192.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges